G01N 2800/326
Arrhythmias
Official title: Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes
G01N2800/326 (Arrhythmias) appears on 49 US grants and 123 published applications in this corpus.
Search patents in G01N- Granted patents
- 49
- Published applications
- 123
- Assignees
- 84
- Inventors
- 232
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 5 |
| 2005 | 0 | 4 |
| 2006 | 1 | 1 |
| 2007 | 1 | 3 |
| 2008 | 2 | 4 |
| 2009 | 5 | 7 |
| 2010 | 1 | 4 |
| 2011 | 0 | 4 |
| 2012 | 0 | 5 |
| 2013 | 3 | 8 |
| 2014 | 0 | 4 |
| 2015 | 4 | 6 |
| 2016 | 1 | 4 |
| 2017 | 2 | 13 |
| 2018 | 3 | 9 |
| 2019 | 4 | 7 |
| 2020 | 2 | 2 |
| 2021 | 6 | 12 |
| 2022 | 1 | 4 |
| 2023 | 3 | 8 |
| 2024 | 2 | 2 |
| 2025 | 5 | 2 |
| 2026 | 2 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Biomarkers for the diagnosis of atrial fibrillation cause of stroke25 Aug 2026US 12,716,097 B2Ischemia Care LLC
- Methods and compositions for cardiovascular disease detection and management31 Mar 2026US 12,590,974 B2Ohio State Innovation Foundation
- Systems and methods for modeling disease and assessing adverse side effects of therapeutics therefor23 Dec 2025US 12,503,717 B2Novoheart International Limited
- Circulating ESM-1 (endocan) in the assessment of atrial fibrillation and/or stroke25 Nov 2025US 12,480,959 B2Academisch Ziekenhuis Maastricht
- Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications18 Nov 2025US 12,474,326 B2Tabula Rasa Healthcare, Inc.
- Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications13 Aug 2026US 2026/0235578 A1Tabula Rasa Healthcare, Inc.
- Methods and compositions for cardiovascular disease detection and management16 Jul 2026US 2026/0202425 A1Ohio State Innovation Foundation
- Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter5 Mar 2026US 2026/0060955 A1Amarin Pharmaceuticals Ireland Limited
- Experimental method for clinical research of targeting molecules based on atrial fibrillation warning system8 Jan 2026US 2026/0007351 A1Pla General Hospital of Northern Theater Command
- Method for the prognosis of patients suffering from atrial fibrillation11 Sep 2025US 2025/0283893 A1
Most cited
By later US patents
- Methods for identifying patients at risk for life threatening arrhythmias42US 7,622,303 B2Medtronic, Inc. · 2009
- Markers for differential diagnosis and methods of use thereof38US 7,713,705 B2Biosite, Inc. · 2010
- Identifying patients at risk for life threatening arrhythmias35US 7,608,458 B2Medtronic, Inc. · 2009
- Compositions and methods for modulating connexin hemichannels28US 7,153,822 B2Wyeth · 2006
- Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments19US 9,612,234 B2ACEA Biosciences, Inc. · 2017